Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
Net Proceeds from Stock Offering: Approximately $94 million from an offering announced on November 5, 2025. Private Financing: $160 million with net proceeds of approximately $150 million. Research and Development Expense: $8.1 million for Q4 2025, a decrease from $11 million in Q4 2024. General and Administrative Expense: $12.3 million for Q4 2025, an increase from $8.1 million in Q4 2024. Net Cash Used in Operating Activities: $14.6 million for Q4 2025, compared to $8.8 million in Q4 2024. Net Loss: $19.9 million or $0.27 per share for Q4 2025, compared to $18.7 million or $0.62 per share for Q4 2024. Warning! GuruFocus has detected 3 Warning Signs with RLMD. Is RLMD fairly valued? Test your thesis with our free DCF calculator. Release Date: March 19, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Relmada Therapeutics Inc ( NASDAQ:RLMD ) reported compelling 12-month efficacy data for the
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics (RLMD) had its price target raised by Mizuho from $10.00 to $19.00. They now have an "outperform" rating on the stock.MarketBeat
- Relmada (RLMD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics GAAP EPS of -$0.27 misses by $0.13 [Seeking Alpha]Seeking Alpha
RLMD
Earnings
- 3/19/26 - Miss
RLMD
Sec Filings
- 3/20/26 - Form 8-K
- 3/19/26 - Form 10-K
- 3/9/26 - Form 8-K
- RLMD's page on the SEC website